

#### MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/23/2016; Page 1

## **SUGGESTED FORMULATION**

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Salicylic Acid (Hydrosoluble, 50%)	2.00	mL				
Medisca VersaPro™ Foam Base	q.s. to 50.0	mL				

## **SPECIAL PREPARATORY CONSIDERATIONS**

<u>Ingredient-Specific Information</u>		
Light sensitive (protect from lig	ght whenever possible):	Salicylic Acid, VersaPro™ Foam Base
Suggested Preparatory Guidelines		C +
Non-Sterile Preparati	ion Sterile Preparation	200
<u>Processing Error /</u> <u>Testing Considerations</u> :	1	considerations during preparation, it is suggested to of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coshould always be worn.	oat, disposable gloves, eyewear and face-masks
		very small quantities of ingredients. All calculations be verified before dispensing the final product.



### MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/23/2016; Page 2

Suggested Formula	Salicylic Acid 2% Topical Foam (Solution, 50 mL)	FIN	F 006 816v2
----------------------	--	-----	-------------

## **SUGGESTED PREPARATION (for 50 mL)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Salicylic Acid (Hydrosoluble, 50%) §	2.00	mL			
Medisca VersaPro™ Foam Base §	q.s. to 50.0	mL			

- § Weigh / measure just prior to use.
- \* Takes into account increased batch size conversions and density conversions, if required.

Prepai	ratory	Instruct	10 <b>n</b>

## 1. Filling to volume:

A. Incrementally add the VersaPro<sup>TM</sup> Foam Base to the Salicylic Acid (Hydrosoluble, 50%) to fill to the required batch size (50.0 mL *plus* processing error adjustments).

Specifications: Continuously mix.

End result: Homogeneous liquid-like solution.

# 2. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging requirements").



#### MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

8/23/2016; Page 3

Suggested Formula	Salicylic Acid 2% Topical Foam (Solution, 50 mL)	FIN	F 006 816v2
----------------------	--	-----	-------------

#### SUGGESTED PRESENTATION

Ī	JOEOTED I KI		I I I I I I I I I I I I I I I I I I I			- Tightly closed, light-resistant topical dispensing		
	Estimate Beyond-Use Dat		30 days, as per USP.	Packa Requirem		bottle.  - To be administered with a metered-dose measuring device.		
		1	Use as directed. Do not exceed prescribed dose.			Cap tightly after use.		
		2	Keep out of reach of children.		6	Protect from light.		
	Auxiliary Labels	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.			For external use only.		
	4 Keep at room temperature (20°C – 23°C).							
	Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.						
	Patient Instructions	Contact your pharmacist in the event of adverse reactions.  IMPORTANT: The quantity of API administered is directly dependent on the quantity of product applied.						

#### **REFERENCES**

	211025					
1.	Cosmetics for special populations and for use as vehicles. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 441.					
2. Salicylic Acid. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 <sup>th</sup> Edition. London, E Pharmaceutical Press; 2009: 1612.						
3.	Salicylic Acid (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #8469.					
4.	Salicylic Acid. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2012: 432.					
5.	Salicylic Acid (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 5779.					
6.	USP <795>. <i>United States Pharmacopeia XXXIX / National Formulary 34.</i> Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 617.					

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.